New Oral Antitumor Drugs and Medication Safety in Uro-Oncology: Implications for Clinical Practice Based on a Subgroup Analysis of the AMBORA Trial

New Oral Antitumor Drugs and Medication Safety in Uro-Oncology: Implications for Clinical Practice Based on a Subgroup Analysis of the AMBORA Trial

Oral antitumor therapeutics (OAT) bear a high risk for medication errors, e.g., due to drug–drug or drug–food interactions or incorrect drug intake. Advanced age, organ insufficiencies, and polymedication are putting uro-oncological patients at an even larger risk. This analysis sets out to (1) inve...

Full description

Bibliographic Details
Main Authors: Katja Schlichtig, Lisa Cuba, Pauline Dürr, Laura Bellut, Norbert Meidenbauer, Frank Kunath, Peter J. Goebell, Andreas Mackensen, Frank Dörje, Martin F. Fromm, Bernd Wullich
Format: Article
Language:English
Published: MDPI AG 2022-08-01
Series:Journal of Clinical Medicine
Subjects:
drug–related problems
medication errors
medication safety
prostate cancer
renal cell carcinoma
Online Access:https://www.mdpi.com/2077-0383/11/15/4558

Internet

https://www.mdpi.com/2077-0383/11/15/4558

Similar Items